Acute Coronary Syndromes Heart failure Acute Coronary Syndromes Myocardial in fraction Heart failure Sodium glucose cotransporter 2 inhibitors (SGLT2i)
Conditions
Interventions
This group is control group. The patient receive standard treatment and does not add intervention.,Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are oral hypoglycemic agents that reduce plasma
Conventional treatment,SGLT2i (empaglifozin 10 mg or dapaglifozin 10 mg)
Sponsors
Faculty of Medicine, Chiang Mai University
The Faculty of Medicine endowment Fund,
Chiang Mai University
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Male or female patients 35 years of age 2.Diagnosis of ACS based on the 4th universal definition between 24 hours and 10 days before treatment allocation 3.LVEF 40 percent after index MI or 4.LVEF 40 percent with symptomatic heart failure requiring iv diuretic or elevate natriuretic peptides NT-proBNP600 pg ml, if atrial fibrillation or flutter 900 pg ml with Killip class II to IV 5.Hemodynamic stable defined as SBP 100 mmHg at initiation of treatment, no symptomatic hypotension 6.No increase in intravenous diuretics 7.No intravenous inotrope or intravenous vasodilators 8.Received revascularization to IRA with PCI
Exclusion criteria
Exclusion criteria: 1.Cardiogenic shock within last 24 hours prior to the screening 2.Planned CABG or cardiac surgery within next 3 months 3.Symptomatic hypotension at screening 4.Stroke or TIA 1 month prior to the screening 5.History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time 6.Impaired renal function, defined as GFR < 30 ml/min (MDRD formula) at screening 7.Diagnosis of Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA) 8.Life expectancy < 1 year 9. Prior diagnosis of heart failure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outpatient HF or hospitalization for HF 12 months Number of OPD and IPD visit,Outpatient HF or hospitalization for HF 12 months number of OPD and IPD visit,Outpatient HF or hospitalization for HF 12 months number of OPD and IPD visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Orthostatic hypotension day 1 to day 365 Blood pressure,Worsening of renal function week 2 eGFR level,Proportional change in plasma NT-proBNP week 2 and week 6 NT-proBNP level,3-point MACE 1 year Number of MACE event,LV remodeling 6 week Percentage of LVEF from Echocardiogram,LV remodeling 6 week Percentage of LVEF from Cardiac MRI,Mitochondrial function and metobolomic function 1 year Mitochondrial and metobolomic activity | — |
Countries
Thailand
Contacts
Public ContactPannipa Suwannasom
Faculty of Medicine, Chiang Mai University
Outcome results
None listed